- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02573038
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID). (ASTRID)
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients.
Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations.
They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis. Choroidal neovascularization (CNV) represents the most frequent complication for those patients. It leads to a rapid and important loss of visual acuity. CNV in angioid streaks represent the fourth leading cause of CNV in young patients.
CNV in angioid streaks is treated at the moment with off-label anti-VEGF (Vascular Endothelial Growth Factor) therapy and could also benefit from aflibercept (EYLEA), a new anti-VEGF currently indicated in AMD. Case reports suggest that such patients would not need as many injections as in AMD.
ASTRID is an open-label, single arm, prospective, multicenter, phase II study. The main objective is to demonstrate the effectiveness in clinical terms after 52 weeks of treatment with aflibercept on the visual acuity of patients affected by CNV in angioid streaks. A specific dosage regimen is designed to achieve maximum efficiency. The patients are followed on a monthly basis until 52 weeks. Six injections are mandatory, the other ones are injected only in case of active CNV.
Study Overview
Status
Intervention / Treatment
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 < Age < 50 years old
- Patient who give voluntary signed informed consent
- Patient affiliated with the French universal health care system or similar
- Patient with CNV in angioid streaks, whatever caused the angioid streaks, with active primary subfoveal, retrofoveal or juxtafoveal lesions that affect the fovea as evidenced by angiography (fluorescein and/or indocyanine green) and/or SD-OCT in the studied eye
- Patient willing, committed and able to return for all clinic visits and complete all study-related procedures
Exclusion Criteria:
- Pregnant women
- Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study
- Patient who is protected adults according to the terms of the law (French public health laws)
- Involvement in another clinical trial (studied eye and/or the other eye)
Patient with non-angioid streaks CNV, especially:
- AMD
- High myopia defined as refraction ≥ - 6 diopters
- Other curative treatment of CNV in angioid streaks in the studied eye during the last 3 months before the first intravitreal injection: anti-VEGF therapy, juxta- or extra-foveal macular laser, photodynamic therapy, surgery, external radiotherapy, transpupillary thermotherapy ...
- Medical history of retrofoveal focal macular laser photocoagulation in the studied eye
- Subretinal hemorrhage reaching the fovea center or with a size > 50% of the lesion area
- Fibrosis or retrofoveal retinal atrophy in the studied eye
- Retinal pigment epithelial tear reaching the macula in the studied eye
- Medical history of intravitreal medical device in the studied eye
- Medical history of auto-immune or idiopathic uveitis
- Proved diabetic retinopathy
- Intra-ocular pressure ≥ 25 mmHg despite two topical hypotonic treatments
- Aphakia or lack of lens capsule (not removed by YAG laser) in the studied eye
- Arterial hypertension that is not controlled by an appropriate treatment and defined by one measure of systolic blood pressure > 180mmHG or 2 consecutive measures > 160mmHg, or by a diastolic blood pressure > 100mmHg
- Antecedents of cerebrovascular disease or myocardial infarction during the last 6 months before inclusion (J1)
- Antecedents of any pathology, metabolic disease, or any serious suspicion of disease during the clinical or laboratory exam that would contraindicate the use of the product, could affect the interpretation of the study results or lead to major risks of complication for the subject
- Renal insufficiency requiring dialysis or renal transplantation
- Previous (less than a year) or actual treatment with systemic administration of anti-VEGF therapy
- Known hypersensitivity to aflibercept, or another drug composite of the medicinal product used; allergy to fluorescein, indocyanine green, anaesthetic eye drops
- Active or suspected ocular or peri-ocular infection
- Active severe intraocular inflammation
- Medical history of intra-ocular surgery within 28 days before the first injection in the studied eye
- Any illness or ocular condition that would require an intra-ocular surgery in the studied eye within 12 months after the inclusion
- Follow up not possible during 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aflibercept
Intravitreal injection of aflibercept (EYLEA) / 2mg
|
The patients are followed on a monthly basis until 52 weeks.
Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44.
During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in best corrected visual acuity (BCVA) from baseline to 52 weeks in patients with choroidal neovascularization in angioid streaks treated with Aflibercept
Time Frame: 52 weeks
|
Change in BCVA number of letters gained or lost between baseline and 52 weeks.
BCVA is measured on the scale Early Treatment Diabetic Retinopathy Study (ETDRS) at an initial distance of 4 meters.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Side-effects observed during the study
Time Frame: 52 weeks
|
52 weeks
|
|
Mean change in BCVA from baseline to 24 weeks
Time Frame: 24 weeks
|
Mean change in BCVA expressed as number of letters gained or lost measured with ETDRS scale from baseline to week 24
|
24 weeks
|
Percentage of patients who lost fewer than 15 letters of BCVA from baseline to 24 weeks.
Time Frame: 24 weeks
|
percentage of the patients who lost fewer than 15 letters of BCVA measured with ETDRS scale from baseline to week 24.
|
24 weeks
|
Percentage of patients who lost fewer than 15 letters of BCVA from baseline to 52 weeks
Time Frame: 52 weeks
|
Percentage of the patients who lost fewer than 15 letters of BCVA measured with ETDRS scale from baseline to week 52.
|
52 weeks
|
number of injections per patient for 52 weeks
Time Frame: 52 weeks
|
52 weeks
|
|
Average change in central retinal thickness (CRT) between baseline and 24 weeks
Time Frame: 24 weeks
|
Average change in central retinal thickness (CRT) in micrometers measured with Spectral domain Optical Coherence Tomography (SD-OCT) from baseline to week 24
|
24 weeks
|
Average change in central retinal thickness (CRT) between baseline and 52 weeks
Time Frame: 52 weeks
|
Average change in central retinal thickness (CRT) in micrometers measured with Spectral domain Optical Coherence Tomography (SD-OCT) from baseline to week 52
|
52 weeks
|
Mean change in neovascular lesion size between baseline and 52 weeks.
Time Frame: 52 weeks
|
change in neovascular lesion size measured with fluorescein and/or indocyanine green angiography from baseline to week 52
|
52 weeks
|
Mean change in neovascular lesion morphology between baseline and 52 weeks.
Time Frame: 52 weeks
|
Mean change in neovascular lesion morphology measured with fluorescein and/or indocyanine green angiography from baseline to week 52
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Retinal Diseases
- Uveal Diseases
- Choroid Diseases
- Metaplasia
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Angioid Streaks
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
Other Study ID Numbers
- 2014.878
- 2014-003661-18 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Choroidal Neovascularization in Angioid Streaks
-
Asociación para Evitar la Ceguera en MéxicoUnknownChoroidal Neovascularization | Angioid StreaksMexico
-
University of Illinois at ChicagoGenentech, Inc.Withdrawn
-
University of Campania "Luigi Vanvitelli"Completed
-
The Filatov Institute of Eye Diseases and Tissue...Odessa National Medical University; Mykolaiv Region Ophthalmogical Hospital; Central...UnknownAngioid Streaks of MaculaUkraine
-
Instituto Universitario de Oftalmobiología Aplicada...CompletedChoroidal Subfoveal/Juxtafoveal Neovascularization in High MyopiaSpain
-
Hospices Civils de LyonCompletedInflammatory Choroidal NeovascularizationFrance
-
Jiao MingfeiUnknownIdiopathic Choroidal NeovascularizationChina
-
Massachusetts Eye and Ear InfirmaryWithdrawnChoroidal Neovascularization | Myopia | Angioid Streaks | Multifocal Choroiditis | Punctate Inner Choroidopathy (PIC) | Ocular Histoplasmosis Syndrome | Central Serous Chorioretinopathy (CSC) | Trauma, or Hereditary Eye Diseases
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Hospices Civils de LyonCompletedStudy Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients (INTUITION)Idiopathic Choroidal NeovascularizationFrance
Clinical Trials on Aflibercept
-
Regeneron PharmaceuticalsSanofiCompletedSolid TumorsUnited States, Canada
-
CR-CSSS Champlain-Charles-Le MoyneSanofi; Regeneron Pharmaceuticals; Quebec Clinical Research Organization in CancerTerminatedMetastatic Colorectal CancerCanada
-
Samsung Bioepis Co., Ltd.CompletedNeovascular Age-related Macular DegenerationCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
-
Alvotech Swiss AGActive, not recruitingNeovascular (Wet) AMDSlovakia, Czechia, Georgia, Japan, Latvia
-
Bioeq GmbHCompletedNeovascular Age-related Macular DegenerationBulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms | Cancer of the OvaryUnited States, France, Canada, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland
-
SanofiRegeneron PharmaceuticalsCompletedOvarian NeoplasmsUnited States, Italy, Sweden
-
SanofiRegeneron PharmaceuticalsCompletedNeoplasms, Lung | Pulmonary DiseasesUnited States, France, Canada
-
Regeneron PharmaceuticalsBayerCompletedNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
Regeneron PharmaceuticalsBayerActive, not recruitingType 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes MellitusUnited States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary